Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBI-2001 (Takara Bio Inc.)
- Development stage
- Unknown
- Lead developer
- Takara Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TBI-2001 is an investigational, allogeneic adoptive cell therapy consisting of natural killer (NK) cells engineered to express a T-cell receptor (TCR) specific for the Melanoma-Associated Antigen A4 (MAGE-A4). Developed by Takara Bio, the therapy utilizes NK cells that are modified to express a TCR recognizing MAGE-A4 peptides presented by HLA-A*24:02 on the surface of cancer cells. This TCR-NK approach aims to combine the antigen-targeting precision of TCRs—which can recognize intracellular tumor antigens—with the innate cytotoxic potential and favorable safety profile of NK cells, potentially providing an off-the-shelf treatment option. TBI-2001 is currently being evaluated in clinical trials for the treatment of MAGE-A4-positive solid tumors, such as synovial sarcoma and various carcinomas.
- Other names
- MAGE-A4 TCR-NKMAGE-A-4 TCR-NKMAGE-A 4 TCR-NKMAGE TCR-NKTCR-NK MAGE-A4
02
Targets
MAGE-A4 peptide-HLA-A*02:01 complex
Beyond the preview
Go deeper on TBI-2001 (Takara Bio Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBI-2001 (Takara Bio Inc.).